Tuesday, January 19, 2021
Home Tags Tumors

Tag: Tumors

The cancer microbiome reveals which bacteria live in tumors

IMAGE: A diagram of the species of bacteria from an individual patient that are more...

BET Inhibitor CC-90010 Shows Activity in Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin...

The reversible BET inhibitor CC-90010 was found to have preliminary antitumor activity in patients with heavily pretreated, advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma,...

New breast cancer drug shows promise, boosts the body’s ability to...

CHAPEL HILL, N.C. — A signaling pathway in the body that helps fight off infections may also hold the key to a breakthrough in...

Experts Reflect on Most Impactful FDA Moves of 2020 in Solid...

Despite the rapid spread of the coronavirus disease 2019 (COVID-19) that plagued not only the oncology field but the healthcare system as a whole,...

GSRGT 2020: SWOG S1823 – MicroRNA 371 for Outcome Prediction in...

(Urotoday.com)  The newly formed Global Society of Rare Genitourinary Tumors (GSRGT) held its inaugural meeting, focusing on penile and testicular cancer. The session held Saturday,...

Immunicum AB (publ) Receives FDA Fast Track Designation for Ilixadencel in...

Press Release 7 December 2020 Immunicum AB (publ) Receives FDA Fast Track Designation for Ilixadencel in Gastrointestinal Stromal Tumors...

Turnstone Biologics Announces First Patients Enrolled in Phase 1/2 Clinical Trial...

Turnstone Biologics Announces First Patients Enrolled in Phase 1/2 Clinical Trial Evaluating RIVAL-01 For the Treatment of Solid Tumors Details Category: DNA RNA and...

Novel Small Molecule +/- Pembrolizumab Induces Responses in Various Solid Tumors...

The oral small molecule FLX475 demonstrated promise when administered either alone or in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) in multiple solid...

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Patients...

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express PD-L1...

KRAS G12C Inhibitor Shows Promising Effects in NSCLC, Other Solid Tumors

A pair of abstracts based on a phase 1/2 trial of adagrasib (MRTX849) a KRAS G12C inhibitor, showed promising results for patients with lung,...
20,764FansLike
2,507FollowersFollow
16,600SubscribersSubscribe

EDITOR PICKS